ライフサイエンスコーパス: microvascular disease

1 of macrovascular disease and 1,345 cases of microvascular disease.

2 he relationship between retinal and systemic microvascular disease.

3 acute manifestations of progressive cerebral microvascular disease.

4 rve mobility in elderly people with cerebral microvascular disease.

5 the kidney, which, in turn, is the result of microvascular disease.

6 >10 years] diabetes) to assess the impact of microvascular disease.

7 sequence more closely associated with strial microvascular disease.

8 ntolerance, electroretinographic defects, or microvascular disease.

9 Diabetes increases the risk for microvascular disease.

10 ovide evidence of its complicity in diabetic microvascular disease.

11 ts in the genetic contribution to macro- and microvascular disease.

12 einaemia and AD could be linked by stroke or microvascular disease.

13 erence in susceptibility to diabetes-induced microvascular disease.

14 (stent) <2.0, a normal rCVR supported global microvascular disease.

15 vents most end-stage complications caused by microvascular disease.

16 mechanisms for the onset and progression of microvascular diseases.

17 ssive weight is a well-known risk factor for microvascular diseases.

18 diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reduction

19 Microvascular disease, a characteristic of acute and chr

20 arvovirus B19 (B19V) is a common pathogen in microvascular disease and cardiomyopathy, owing to infec

21 The benefits of fenofibrate for microvascular disease and its potential role in combinat

22 s hold promise for the treatment of diabetic microvascular disease and peripheral artery disease but

23 an intriguing positive relationship between microvascular disease and treatment with statins and tac

24 t be a useful screening test for generalized microvascular disease and, if detected, might reasonably

25 atherosclerosis, hyperglycemia, which causes microvascular disease, and hypertension.

26 s-related end point, diabetes-related death, microvascular disease, and stroke in the group receiving

27 e of inflammation and the onset of diabetes, microvascular diseases, and periodontal pathologies.

28 transplant patients and the determinants of microvascular disease are not known.

29 Both coronary macrovascular and microvascular disease are prognostically important.

30 Cerebral microvascular disease associated with type 2 diabetes ma

31 Recent studies highlight the importance of microvascular disease, autoimmunity, and fibroblast diff

32 oth epicardial (beta = -0.57, p < 0.001) and microvascular disease (beta = -0.60, p < 0.001) on stepw

33 The effect of total microvascular disease burden on cardiovascular disease r

34 mination showed significant improvement when microvascular disease burden was added to models.

35 Chronic hyperglycaemia and microvascular disease contribute to cognitive dysfunctio

36 Microvascular disease correlated positively with donor a

37 Microvascular disease, diabetic foot, cerebrovascular di

38 allel increases in bAPV and hAPV, "acquired" microvascular disease due to distal microembolization or

39 white matter injury associated with cerebral microvascular disease extends well beyond what can be id

40 Pre-diabetes has only a minor impact on microvascular disease; glucose-lowering drugs can delay

41 obin level) is related to the development of microvascular disease; however, the relation of glycosyl

42 biopsy revealed more advanced grade C and D microvascular disease in 45% and 36% of the patients, re

43 ibition might be a novel strategy to prevent microvascular disease in diabetes and other diseases.

44 Microvascular disease in diabetes extends to the brain.

45 impair insulin sensitivity and contribute to microvascular disease in diabetes mellitus.

46 An increased risk of microvascular disease in NPH versus basal after 3 OGLDs,

47 We hypothesized that preexisting brain microvascular disease in patients with diabetes might pa

48 a, and hence accelerated atherosclerosis and microvascular disease in T2DM, obesity, and related synd

49 (NO) and free radicals in the development of microvascular disease in type 1 diabetes remains unclear

50 of age and is commonly associated with other microvascular disease, including nephrosclerosis and dia

51 Microvascular disease increases with donor age.

52 Diabetes-specific microvascular disease is a leading cause of blindness, r

53 the drug approach will delay development of microvascular disease is in dispute.

54 If one of the key mechanisms of brain microvascular disease is leakage of serum proteins into

55 We then show that dose-dependent microvascular disease is seen in a transgenic mouse mode

56 inflammation in the development of diabetic microvascular diseases is still unclear, it is likely th

57 tes, supporting the hypothesis that cerebral microvascular disease may contribute to their observed a

58 To determine the added effect of microvascular disease, measurements of flow reserve were

59 res of cerebrovascular disease because brain microvascular disease occurs gradually and insidiously.

60 t the importance of BP on the progression of microvascular disease of the brain, which has been assoc

61 Affected patients have microvascular disease of the kidneys, heart, and brain.

62 and mostly because of an intrinsic cerebral microvascular disease of unknown cause.

63 Such events may arise from spasm, microvascular disease, or other pathways.

64 ion, acute coronary syndrome and stroke) and microvascular disease (peripheral neuropathy, nephropath

65 Cerebral microvascular disease predominantly affects brain white

66 Skin AGEs are robust long-term markers of microvascular disease progression, emphasizing the impor

67 Ischemia in AS is not related to microvascular disease; rather, it is driven by abnormal

68 The Coronary Slow-flow and Microvascular Diseases Registry [MICAT]; NCT02180178).

69 The benefits of fibrates on microvascular disease remain to be fully explored.

70 ticipants had preexisting cardiovascular and microvascular disease, respectively; mean HbA1c level wa

71 en MRI findings and four findings of retinal microvascular disease: retinopathy, focal arteriolar nar

72 The cumulative burden of microvascular disease significantly affects the risk of

73 To date, the drug approach to prevention of microvascular disease starting with pre-diabetes has not

74 For individuals with one, two, or three microvascular disease states versus none, the multivaria

75 lesterolemia, T2D-macrovascular disease, T2D-microvascular disease, T2D-neuropathy, T2D-carpal-tunnel

76 ress, plays an important role in the retinal microvascular disease that is characteristic of diabetic

77 r; however, in individuals with diabetes and microvascular disease these cells are dysfunctional.

78 There was no evidence of microvascular disease until 12 months, when trypsin dige

79 Microvascular disease violates the integrity of the bloo

80 Coronary microvascular disease was classified by light microscopy

81 The evidence-based reduction in risk of microvascular disease with glucose lowering has resulted

82 ation of serum proteins as a result of brain microvascular disease would account for the perivascular

83 First, brain microvascular disease would not be recognized by traditi